The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

Apoptosis, as a very important biological process, is a response to developmental cues or cellular stress. Impaired apoptosis plays a central role in the development of cancer and also reduces the efficacy of traditional cytotoxic therapies. Members of the B-cell lymphoma 2 (BCL-2) protein family ha...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in oncology Ročník 12; s. 985363
Hlavní autoři: Qian, Shanna, Wei, Zhong, Yang, Wanting, Huang, Jinling, Yang, Yinfeng, Wang, Jinghui
Médium: Journal Article
Jazyk:angličtina
Vydáno: Frontiers Media S.A 12.10.2022
Témata:
apoptosis
autoimmunity
Bcl-2
cancer
Oncology
systematic
ISSN:2234-943X, 2234-943X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Apoptosis, as a very important biological process, is a response to developmental cues or cellular stress. Impaired apoptosis plays a central role in the development of cancer and also reduces the efficacy of traditional cytotoxic therapies. Members of the B-cell lymphoma 2 (BCL-2) protein family have pro- or anti-apoptotic activities and have been studied intensively over the past decade for their importance in regulating apoptosis, tumorigenesis, and cellular responses to anticancer therapy. Since the inflammatory response induced by apoptosis-induced cell death is very small, at present, the development of anticancer drugs targeting apoptosis has attracted more and more attention. Consequently, the focus of this review is to summarize the current research on the role of BCL-2 family proteins in regulating apoptosis and the development of drugs targeting BCL-2 anti-apoptotic proteins. Additionally, the mechanism of BCL-2 family proteins in regulating apoptosis was also explored. All the findings indicate the potential of BCL-2 family proteins in the therapy of cancer.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Gavin P. McStay, Liverpool John Moores University, United Kingdom
Reviewed by: Jiann-Ruey Hong, National Cheng Kung University, Taiwan; Dharmendra Kumar Yadav, Gachon University, South Korea; Manzar Alam, University of Texas Southwestern Medical Center, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.985363